NCT03167255View on ClinicalTrials.gov

Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 6, 2017

Primary Completion Date

October 20, 2021

Study Completion Date

November 15, 2021

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

NS-065/NCNP-01

Received during weekly intravenous infusions

Trial Locations (6)

23298

Children's Hospital of Richmond at VCU, Richmond

27710

Duke University Medical Center, Durham

60611

Lurie Children's Hospital, Chicago

63110

Washington University, St Louis

95817

UC Davis, Sacramento

Unknown

Alberta Children's Hospital, Calgary

Sponsors

Lead Sponsor

NS Pharma, Inc.

Collaborators (1)

Nippon Shinyaku Co., Ltd.
All Listed Sponsors
collaborator

Nippon Shinyaku Co., Ltd.

INDUSTRY

collaborator

Cooperative International Neuromuscular Research Group

NETWORK

collaborator

Therapeutic Research in Neuromuscular Disorders Solutions

INDUSTRY

lead

NS Pharma, Inc.

INDUSTRY

NCT03167255 - Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) | Biotech Hunter | Biotech Hunter